on ABIVAX (EPA:ABVX)
Abivax: Presentation of promising data on obefazimod at the 2025 UEG congress
Abivax announced the presentation of recent results for obefazimod at the European Union of Gastroenterology 2025 Congress in Berlin. The data come from the ABTECT phase 3 trial, which examines the treatment's efficacy after eight weeks in patients with ulcerative colitis. The presentation is scheduled for October 6 at 10:00 a.m. CET.
Abivax will also hold a conference call for analysts and investors to discuss these results in detail on the same day at 3:00 PM CET. A symposium titled "From Evolution to Revolution" will present new therapeutic approaches for this disease. This initiative reflects Abivax's commitment to exploring innovative solutions for chronic inflammatory diseases.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news